Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Non-cash Items (2016 - 2024)

Historic Non-cash Items for Anika Therapeutics (ANIK) over the last 11 years, with Q3 2024 value amounting to $248000.0.

  • Anika Therapeutics' Non-cash Items rose 238000.0% to $248000.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $248000.0, marking a year-over-year increase of 238000.0%. This contributed to the annual value of $127000.0 for FY2023, which is 8790.48% down from last year.
  • Anika Therapeutics' Non-cash Items amounted to $248000.0 in Q3 2024, which was up 238000.0% from $300000.0 recorded in Q2 2024.
  • In the past 5 years, Anika Therapeutics' Non-cash Items ranged from a high of $4.7 million in Q3 2021 and a low of $9000.0 during Q1 2022
  • In the last 5 years, Anika Therapeutics' Non-cash Items had a median value of $274000.0 in 2024 and averaged $814857.1.
  • In the last 5 years, Anika Therapeutics' Non-cash Items crashed by 9832.4% in 2022 and then surged by 692222.22% in 2023.
  • Over the past 5 years, Anika Therapeutics' Non-cash Items (Quarter) stood at $2.8 million in 2020, then tumbled by 65.18% to $975000.0 in 2021, then grew by 7.69% to $1.0 million in 2022, then crashed by 87.9% to $127000.0 in 2023, then surged by 95.28% to $248000.0 in 2024.
  • Its last three reported values are $248000.0 in Q3 2024, $300000.0 for Q2 2024, and $316000.0 during Q1 2024.